VIVELLE
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVELLE is a transdermal estradiol film (extended-release formulation) approved in 2000 by Novartis. The product delivers estrogen systemically across the skin, bypassing first-pass metabolism. It is indicated for hormone replacement therapy and menopausal symptom management in eligible patients.
LOE Approaching
Product faces lifecycle transition with moderate competitive pressure (30/100), indicating defensive positioning and potential team restructuring as exclusivity erodes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VIVELLE offers limited career growth opportunities given zero linked job postings and approaching LOE status. Roles available are primarily defensive commercial positions focused on market maintenance and managed decline rather than expansion.
Brand ManagerField Sales Representative
Worked on VIVELLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.